According to a research report published by Morgan Stanley, the 6-month survival rate for first-line non-small cell lung cancer in first-line non-small cell lung cancer announced by WCLC is positive, indicating that the early objective remission rate can be transformed into durability, which is an important clinical milestone for the company. The bank believes that risk-return is now biased positively, and raised the rating from “synchronizing with the market” to “increasing holdings”, and the target price was raised from HK$85 to HK$93. Next, we will focus on ESMO's October data on LBL-024 in EP-NEC, biliary tract cancer, small cell lung cancer, and LBL-034, as well as the National Drug Administration's approval of LBL-024 at the frontline EP-NEC and above, and potential business development progress.

According to a research report published by Morgan Stanley, the 6-month survival rate for first-line non-small cell lung cancer in first-line non-small cell lung cancer announced by WCLC is positive, indicating that the early objective remission rate can be transformed into durability, which is an important clinical milestone for the company. The bank believes that risk-return is now biased positively, and raised the rating from “synchronizing with the market” to “increasing holdings”, and the target price was raised from HK$85 to HK$93. Next, we will focus on ESMO's October data on LBL-024 in EP-NEC, biliary tract cancer, small cell lung cancer, and LBL-034, as well as the National Drug Administration's approval of LBL-024 at the frontline EP-NEC and above, and potential business development progress.